Assessing the Impact of dTMS on Neural Targets Associated With Alcohol Use Disorder (NCT06949423) | Clinical Trial Compass
RecruitingNot Applicable
Assessing the Impact of dTMS on Neural Targets Associated With Alcohol Use Disorder
United States100 participantsStarted 2025-12-17
Plain-language summary
The purpose of this study is to evaluate the efficacy of deep transcranial magnetic stimulation as a treatment for Veterans with Alcohol Use Disorder (AUD) to decrease the exceedingly high rate of relapse associated with this condition.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18-75.
* Current DSM-5 diagnosis of moderate to severe AUD (\≥4 diagnostic symptoms).
* Ability to obtain a Motor Threshold (MT) will be determined during the screening process.
* Has an adequately stable condition and environment to enable attendance at scheduled clinic visits.
* Able to read, understand and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments.
* If on a medication regimen for comorbid symptoms, that regimen will be stable for the duration of the study and patient will be willing to remain on this regimen during the treatment phase.
* Fluency in English.
Exclusion Criteria:
* Transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI) contraindications: such as a cardiac pacemaker, cochlear implant, or an implanted device (deep brain stimulation, metal in the head, metal in the body, claustrophobia, pregnant or breastfeeding or other ferromagnetic device/objected in the head and body within 30 cm of the treatment coil.
* General medical condition, disease or neurological disorder that interferes with the assessments or participation.
* Unable to safely withdraw, at least two weeks prior to treatment, from medications that increase seizure risk.
* Current substance abuse (except caffeine or nicotine) as determined by positive toxicology screen.
* Have a mass lesion, cerebral infarct, or other active CNS disease, including an alcohol-related seizure…
What they're measuring
1
Change in Dorsal Anterior Cingulate Cortex Function (dACC) Activation During the FACES Task, Measured via fMRI
Timeframe: 1-4 days post treatment
2
Percentage of Days Abstinent from Alcohol, Assessed by Timeline Followback (TLFB)
Timeframe: 3-months post treatment
3
Percentage of Heavy Drinking Days, Assessed by Timeline Followback (TLFB)